Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
761-780 of 2,120 trials

Zanidatamab for Advanced HER2-Positive Biliary Tract Cancer

We are studying whether zanidatamab combined with standard chemotherapy helps patients with advanced HER2-positive biliary tract cancer more than standard chemotherapy alone. This trial aims to evaluate its effectiveness and safety.

Biliary Tract CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Inflammatory Bowel Disease: Intravenous Lidocaine Study

We are investigating whether intravenous lidocaine can reduce abdominal pain in patients with chronic inflammatory bowel disease. Additionally, we will study how this treatment affects brain activity compared to healthy volunteers.

Inflammatory Bowel Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

HER3-Targeted Imaging with Patritumab Deruxtecan

We are studying the best dose of a new imaging agent for patients with tumors that express HER3. This research aims to improve how we visualize and understand tumor response to treatment.

EGFR Mutation Positive Advanced Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Severe Systemic Lupus Erythematosus: Obecabtagene Autoleucel Study

We are studying a new treatment for patients with severe, hard-to-treat systemic lupus erythematosus. The trial aims to evaluate its safety, tolerability, and early signs of effectiveness.

Severe Systemic Lupus ErythematosusSafety phase (I)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Acute Mesenteric Ischemia: Oral Antibiotics Study

We are investigating whether oral antibiotics can help reduce serious complications in patients with acute mesenteric ischemia. This study compares the effects of antibiotics to a placebo to see if they improve patient outcomes.

Acute Mesenteric Ischemia>2 yearsConfirmation phase (III)Standard MedicinesCardiologyGastroenterology

Psoriatic Arthritis: Tapering Immunosuppressive Therapy

We are studying whether reducing immunosuppressive medication helps adults with psoriatic arthritis maintain stable disease activity. The trial also looks at the safety of this approach.

Psoriatic Arthritis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineRheumatology

Noncardiac Surgery: Noradrenaline Infusion Study

We are investigating if noradrenaline infusion is more effective than standard blood pressure management in preventing low blood pressure during noncardiac surgery. This study aims to improve patient safety and outcomes in the operating room.

Low Blood Pressure During Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOtolaryngology

Ovarian Cancer: SALVOVAR Trial on Chemotherapy Regimens

We are studying whether a new weekly chemotherapy schedule improves outcomes for patients with poor prognostic ovarian cancer compared to the standard treatment. This trial aims to see if it helps with surgery success and overall survival.

Advanced Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Liver Transplant: Regulatory T Cell Therapy

We are studying a new treatment using regulatory T cells for liver transplant recipients to see if it is safe and allows them to stop taking tacrolimus. We also want to learn how it affects graft function and patients' quality of life.

Liver TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: AZD0901 Treatment Study

We are investigating the safety and effectiveness of AZD0901, alone or with other cancer drugs, for patients with advanced solid tumors expressing Claudin 18.2. This study aims to understand how well this treatment may work and its potential side effects.

Gastric CancerGastroesophageal Junction CancerPancreatic Ductal AdenocarcinomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Gastric Cancer: AZD0901 Treatment Study

We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.

Advanced Gastric CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Heart Function Study: Dobutamine in ATTRwt Patients

We are investigating how different doses of dobutamine affect heart performance in patients with wild-type transthyretin amyloid cardiomyopathy. The study also looks at the safety of this treatment.

Wild-type Transthyretin Amyloid Cardiomyopathy1-2 yearsEfficacy phase (II)Standard MedicinesCardiologyInternal Medicine

Urothelial Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.

Urothelial Cancer of the Renal Pelvis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncologyUrology

Treatment-Resistant Depression: P-glycoprotein Study

We are investigating how a protein may affect people with treatment-resistant depression using advanced imaging. This study compares P-glycoprotein activity in those who do not respond to treatment with those who do.

Depression1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Liver Tumors: Indocyanine Green for Better Detection

We are testing whether a dye can help surgeons find liver tumors more easily during surgery. This study aims to improve surgical outcomes and understand how the dye behaves in the liver.

Resectable Malignant Liver Tumor>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart vs. IVIg

We are studying a new treatment called riliprubart to see if it works better than the standard IVIg therapy for people with chronic inflammatory demyelinating polyneuropathy. The trial will evaluate its effects on disability, fatigue, and overall quality of life.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesInternal MedicineNeurology

Relapsed/Refractory T-Cell Leukemia: CD7 CAR T-Cell Therapy

We are testing a new type of T-cell therapy for children and young adults with relapsed or refractory T-cell leukemia or lymphoma. The study aims to find a safe dose and see how well it works.

T-cell Acute Lymphoblastic Leukemia/Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Metastatic Pancreatic Adenocarcinoma: TTX-030 and Chemotherapy

We are studying if adding TTX-030 and possibly budigalimab to standard chemotherapy helps patients with untreated metastatic pancreatic cancer. This trial aims to evaluate the effectiveness and safety of these combinations.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology